MiniMed Group financials
$19.29+2.33%
Close Nov 4, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '27 Jul 31 | Q4 '26 Apr 30 |
|---|---|---|
| Revenue | $843.0M | $837.0M |
| Gross profit | $465.0M | $480.0M |
| Gross margin | 55.2% | 57.3% |
| Operating income | $4.0M | -$93.0M |
| Net income | $0.00 | -$185.0M |
| Net margin | 0.0% | −22.1% |
| Diluted EPS | $0.00 | — |
| EBITDA | $43.0M | -$86.0M |
| Operating cash flow | -$49.0M | — |
| Free cash flow | -$90.0M | — |
| Diluted shares | 281.0M | — |
Balance sheet
| Period end | Jul 31 | Apr 24 |
|---|---|---|
| Cash & equivalents | $207.0M | $298.0M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $4.72B | $4.63B |
| Total liabilities | $1.10B | $1.02B |
| Shareholders' equity | $3.62B | $3.61B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology